For the transaction, the shares of the company are transferred to a new company with the investors partly guaranteed against loss.
B-To-V Partners, a Switzerland-based angel network, and UK-based peer Rosetta Capital have invested €30m ($40m) in 13 out of 25 portfolio companies of Karolinska Development, an independent investment company backing the Sweden-based Karolinska Institute medical university.
The 13 selected companies are: Akinion Pharmaceuticals, Aprea, Axelar, Biosergen, Clanotech, Dilafor, Dilaforette Holding, inhalation Sciences in Sweden, Neodynamics, Nova Said, Pergamum, Promimic, Umecrine Mood.
For the transaction, the shares of the company are transferred to a new company with the investors partly guaranteed against…
